Vibrio cholerae, live attenuated
As of the edition of 20 October 2026, Vibrio cholerae, live attenuated is a vaccine component: marketed, first approved in 2016 (US); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Vaccine component
- Brand name
- Vaxchora
- First approved
- 10 June 2016 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Bavarian Nordic
- Registered trials
- 12, 1 stopped early
- Disease areas
- Infections; Digestive system
US protection
US protection ends in 2028.
US protection ends in 2028, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bavarian Nordic. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 5 | 2 | 0 | 0 |
| Phase 4 | 4 | 2 | 1 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bavarian Nordic | Lead sponsor of trials | 2012 to now |